PARP inhibitor BMN-673
13-001857
Phase 1 small_molecule completed
Quick answer
PARP inhibitor BMN-673 for Metastatic Cancer is a Phase 1 program (small_molecule) at BIOMARIN PHARMACEUTICAL INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BIOMARIN PHARMACEUTICAL INC
- Indication
- Metastatic Cancer
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed